Thrombocytopenic purpura immune

Thrombopoietic factors (no recombinant TPO product in clinical use at this time IL-11 [recombinant product oprelvekin] has marketing approval) stimulate the production of megakaryocyte precursors, megakaryocytes, and platelets [8]. Interleukin-11 has many effects on multiple tissues, and can interact with IL-3, TPO, and SCF. AMG 531, a recombinant peptibody in that binds to the thrombopoetin receptor Mpl and stimulates the production of platelets, is in phase 1 and 2 studies and has been shown to safely increase platelet counts in patients with immune thrombocytopenic purpura [9]. 

Suppression of Rh isoimmunization in non sensitized Rh (D)-negative women, immune thrombocytopenic purpura, transfusion to suppress Rh isoimmunization in Rh (D)-negative female children and female adults in their childbearing years... 

Recommend treatment approach for the initial treatment of immune thrombocytopenic purpura (UP). 

Intravenous Immune Globulin (IGIV) IGIV is a product derived from blood plasma from a donor pool similar to the immune globulin (IG) pool, but prepared so it is suitable for intravenous use. IGIV does not transmit infectious diseases. It is primarily used for replacement therapy in primary antibody-deficiency disorders, for the treatment of Kawasaki disease, immune thrombocytopenic purpura, hypogammaglobulinemia in chronic lymphocytic leukemia, and in some cases of HIV infection. 

Idiopathic thrombocytopenic purpura, also referred to as immune thrombocytopenic purpura, is a bleeding disorder characterised by destruction of platelets. Antiplatelet autoantibodies are present, suggesting an autoimmune aetiology. These antibodies label the platelets for destruction by macrophages in the spleen. The condition may be acute or chronic. Acute ITP is the most common form and is found most often in children. Some cases are associated with recent viral infections and immunisations, notably the measles, mumps, rubella (MMR) vaccine. Typically, the disease is transient with no evidence of vaccine-associated recurrence. The peak incidence occurs between the ages of... 

Patients with thrombocytopenia generally tolerate intravenous immunoglobulin well (35). In 16 young patients aged 9 months to 22 years with immune-mediated hemocytopenias (13 with childhood immune thrombocytopenic purpura), who received a total of 210 infusions, minimal adverse effects (transient headaches) were experienced during only four infusions, and later infusions were problem-free in three of the four patients (36). 

Bolton-Maggs PH. The management of immune thrombocytopenic purpura. Curr Paediatr 2002 12 298-303. 

Tsiouris J, Tsiouris N. Hemiplegia as a comphcation of treatment of childhood immune thrombocytopenic purpura with intravenously administered immunoglobulin. J Pediatr 1998 133(5) 717. 

Berkovitch M, Dolinski G, Tauber T, Aladjem M, Kaplinsky C. Neutropenia as a complication of intravenous immunoglobulin (IVIG) therapy in children with immune thrombocytopenic purpura common and non-alarming. Int J Immunopharmacol 1999 21(6) 411-15. 

Glynne P, Salama A, Chaudhry A, Swirsky D, Lightstone L. Quinine-induced immune thrombocytopenic purpura followed by hemolytic uremic syndrome. Am J Kidney Dis 1999 33(l) 133-7. 

Immune thrombocytopenic purpura. For the treatment of hemorrhage associated with immune (or idiopathic) thrombocytopenic purpura (ITP), doses of 1 g/kg daily for 2 to 3 days plus high-dose methylprednisolone are indicated. 

Hib Hemophilus influenzae type b HSCT hematopoietic stem cell transplant IMIG intramuscular immunoglobulin IPV inactivated polio vaccine ITP immune thrombocytopenic purpura IVIG intravenous immunoglobulin LAIV live attenuated influenza vaccine MMR measles-mumps-rubeUa vaccine OPV oral polio vaccine... 

Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002 346 995-1008. 

The drug most commonly used in clinical practice that can produce immune thrombocytopenic purpura is heparin. Other examples are sulfonamides, thiazide diuretics, chlorpropamide, quinidine, and gold. These types of immune thrombocytopenic purpura are reversed when the drug is withdrawn. Molecular mechanisms for the formation of specific drug-dependent antibodies appear to be very similar. The glycoproteins on the platelet surface interact with the drugs to form neo-epitopes. Subsequent... 

---